Related references
Note: Only part of the references are listed.Epigenetic Regulation and Drug Discovery for Cancer Therapy
Bin Yu et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2019)
Histone Deacetylase Inhibitors in Tumor Immunotherapy
Li-Ming Zhao et al.
CURRENT MEDICINAL CHEMISTRY (2019)
Phase I study of domatinostat (4SC-202), a class I histone deacetylase inhibitor in patients with advanced hematological malignancies
Bastian von Tresckow et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2019)
Validation of histone deacetylase 3 as a therapeutic target in castration-resistant prostate cancer
Abigail B. McLeod et al.
PROSTATE (2018)
Targeting Epigenetics in Cancer
Richard L. Bennett et al.
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 58 (2018)
Deregulated expression of HDAC3 in colorectal cancer and its clinical significance
Masoumeh Nemati et al.
ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE (2018)
Clinical Pharmacokinetics and Pharmacodynamics of Panobinostat
Mathilde Van Veggel et al.
CLINICAL PHARMACOKINETICS (2018)
Selective histone deacetylase small molecule inhibitors: recent progress and perspectives
Hai-Tao Qin et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2017)
HDAC1 and HDAC2 integrate the expression of p53 mutants in pancreatic cancer
N. Stojanovic et al.
ONCOGENE (2017)
Targeting triple negative breast cancer with histone deacetylase inhibitors
Palma Fedele et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2017)
Modulation of antitumor immunity with histone deacetylase inhibitors
Tyler R. McCaw et al.
IMMUNOTHERAPY (2017)
Histone Deacetylase Inhibitors as Anticancer Drugs
Tomas Eckschlager et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China
Yuankai Shi et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
The Search for Potent, Small-Molecule HDACIs in Cancer Treatment: A Decade After Vorinostat
Chiara Zagni et al.
MEDICINAL RESEARCH REVIEWS (2017)
Targeting Class I Histone Deacetylases in a Complex Environment
Christopher J. Millard et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2017)
Progress in the Discovery of Macrocyclic Histone Deacetylase Inhibitors for the Treatment of Cancer
Kai Cheng et al.
CURRENT MEDICINAL CHEMISTRY (2017)
Antitumor activity and pharmacologic characterization of the depsipeptide analog as a novel histone deacetylase/ phosphatidylinositol 3-kinase dual inhibitor
Ken Saijo et al.
CANCER SCIENCE (2017)
Synthesis and biological evaluation of largazole zinc-binding group analogs
Bumki Kim et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2017)
Selective Histone Deacetylase Inhibitors with Anticancer Activity
Nan Ma et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2016)
Synthesis and biological evaluation of novel FK228 analogues as potential isoform selective HDAC inhibitors
Koichi Narita et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2016)
Inside HDACs with more selective HDAC inhibitors
Joelle Roche et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2016)
Largazole Analogues Embodying Radical Changes in the Depsipeptide Ring: Development of a More Selective and Highly Potent Analogue
Jehad Almaliti et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Advances in Activity Cliff Research
Dilyana Dimova et al.
MOLECULAR INFORMATICS (2016)
Depletion of γ-catenin by Histone Deacetylase Inhibition Confers Elimination of CML Stem Cells in Combination with Imatinib
Yanli Jin et al.
THERANOSTICS (2016)
Targeting Histone Deacetylases in Diseases: Where Are We?
Rosaria Benedetti et al.
ANTIOXIDANTS & REDOX SIGNALING (2015)
Modular synthesis and biological activity of pyridyl-based analogs of the potent Class I Histone Deacetylase Inhibitor Largazole
Dane J. Clausen et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2015)
Biochemical, biological and structural properties of romidepsin (FK228) and its analogs as novel HDAC/PI3K dual inhibitors
Ken Saijo et al.
CANCER SCIENCE (2015)
FDA Approval: Belinostat for the Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma
Hyon-Zu Lee et al.
CLINICAL CANCER RESEARCH (2015)
Discovery of Novel Class I Histone Deacetylase Inhibitors with Promising in Vitro and in Vivo Antitumor Activities
Yiwu Yao et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Evaluation of class I HDAC isoform selectivity of largazole analogues
Bumki Kim et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2014)
Therapeutic potential of histone deacetylase inhibitors in pancreatic cancer
Wan Feng et al.
CANCER LETTERS (2014)
Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders
Katrina J. Falkenberg et al.
NATURE REVIEWS DRUG DISCOVERY (2014)
Design, synthesis, and biological evaluation of largazole derivatives: alteration of the zinc-binding domain
Jinyue Su et al.
TETRAHEDRON (2014)
Toward isozyme-selective inhibitors of histone deacetylase as therapeutic agents for the treatment of cancer
Sophia N. Ononye et al.
PHARMACEUTICAL PATENT ANALYST (2012)
The Methylation Effect in Medicinal Chemistry
Eliezer J. Barreiro et al.
CHEMICAL REVIEWS (2011)
Total Syntheses of the Histone Deacetylase Inhibitors Largazole and 2-epi-Largazole: Application of N-Heterocyclic Carbene Mediated Acylations in Complex Molecule Synthesis
Bo Wang et al.
JOURNAL OF ORGANIC CHEMISTRY (2011)
Total Synthesis and Biological Evaluation of Largazole and Derivatives with Promising Selectivity for Cancers Cells
Xin Zeng et al.
ORGANIC LETTERS (2010)
Synthesis and Conformation-Activity Relationships of the Peptide Isosteres of FK228 and Largazole
Albert A. Bowers et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2009)
Discovery, biological activity, synthesis and potential therapeutic utility of naturally occurring histone deacetylase inhibitors
Tenaya L. Newkirk et al.
NATURAL PRODUCT REPORTS (2009)
Synthesis and biological activity of largazole and derivatives
Tobias Seiser et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2008)
Isoform-selective histone deacetylase inhibitors
Anton V. Bieliauskas et al.
CHEMICAL SOCIETY REVIEWS (2008)
Total synthesis and molecular target of largazole, a histone deacetylase inhibitor
Yongcheng Ying et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2008)
Total synthesis and biological mode of action of largazole: A potent Class I histone deacetylase inhibitor
Albert Bowers et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2008)
The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men
Xiang-Jiao Yang et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2008)
The first biologically active synthetic analogues of FK228, the depsipeptide histone deacetylase inhibitor
Alexander Yurek-George et al.
JOURNAL OF MEDICINAL CHEMISTRY (2007)
Dimethyl sulfoxide to vorinostat: Development of this histone deacetylase inhibitor as an anticancer drug
Paul A. Marks et al.
NATURE BIOTECHNOLOGY (2007)
Cardiotoxicity of histone deacetylase inhibitor depsipeptide in patients with metastatic neuroendocrine tumors
Manisha H. Shah et al.
CLINICAL CANCER RESEARCH (2006)
A fluorogenic histone deacetylase assay well suited for high-throughput activity screening
D Wegener et al.
CHEMISTRY & BIOLOGY (2003)
Share Paper
